46219 Results in Fundamental Research

Research on a client company covers its business model and strategy and includes financial forecasts, equity valuation and key sensitivities. Quality, transparency and accuracy are at the forefront of each research report produced, which adheres to our research principles and has to pass rigorous quality checks from our department of supervisory analysts, editors and assistants.

Search Related:Fundamental Research·Reports·Trading Ideas

Free

ValuEngine Rating and Forecast Reports provide the most comprehensive and useful report available. ValuEngine's three models: Valuation Model, Forecast Model and Ratings Model are incorporated to give you a well-rounded analysis from three different perspectives.

Search Related:Analytics·Equities·Evaluated Pricing·Fundamental Research·News·Reference Data·Reports

$15 / report

Subscribers receive daily independent equity research idea generation across 1,600 institutional-quality large cap stocks, mid cap stocks, small cap stocks, and ADRs.

Search Related:Analytics·Equities·Evaluated Pricing·Fundamental Research·Market Data·News·Reference Data·Risk·Trading Ideas

30 days free trial; $15,000/yr

Weekly Advisory summaries of the global and U.S. economy and asset allocation including equities, fixed income, sector allocation, and commodities. Implementation ideas for ETFs are also provided.

Search Related:Equities·ETFs·Fixed Income·Fundamental Research·Indices·Macroeconomic Data·Market Data

$175 / month

Weekly Advisory summaries of the global and U.S. economy and asset allocation including equities, fixed income, sector allocation, and commodities. Implementation ideas for ETFs are also provided.

Search Related:Equities·ETFs·Fixed Income·Fundamental Research·Indices·Macroeconomic Data·Market Data

$1,925 / year (one month free)

Access our investment research and ratings on 3,000+ U.S. equities. Here’s why:

We find it. You benefit. 

Cutting-edge technology enables us to scale our forensics accounting expertise across 3000+ stocks. We shine a light in the dark corners of SEC filings so our clients can make safer, more informed decisions. 

We do the diligence on earnings quality and valuation to improve your efficiency and help you fulfill fiduciary duties.

 

Search Related:Equities·Fundamental Research

$20 / month, 14-day free trial

Exchange Traded Fund (ETF) Fact Sheets covering 100% of the US-listed market. Updated daily. Includes: analytics, charts, exposure, holdings, correlations and more.

Search Related:ETFs·Fundamental Research·Reports·Trading Ideas

$40 / month

Keys To This Week, published at the beginning of every week, is a bullet-pointed list of key market factors with accompanying charts that are most likely to influence US financial market direction. It includes a strategic (looking out 1-2 quarters) and tactical (looking out over the next 30 days) analysis of the US financial landscape including US stocks, market sectors, bonds/interest rates, the US Dollar and commodities, with specific investment ideas. The Weekly Wrap-Up, published on Fridays, is the end-of-week companion to our Keys To This Week reports. Weekly Wrap-Up reviews our Monday morning expectations for the US financial markets, explains what actually happened during the course of the week, and then forecasts what this implies for the upcoming week.

Search Related:Analytics·Fundamental Research·Macroeconomic Data·Market Data·Reference Data

2 Weeks Free, then $125/month

ValuEngine complete set of reports including Industry, Rating and Forecast, and Sector reports.

Search Related:Analytics·Equities·Evaluated Pricing·Fundamental Research·News·Reference Data·Reports

$99 / Month

Zacks Equity Research combines the power of the Zacks Rank with the insight provided by experienced equity analysts to create Zacks Research Reports to help you achieve your financial goals.

Search Related:Equities·Featured Products·Fundamental Research·Reports

$24.95/report

Combination package including Eurozone, US, and UK Economic Indicators products. Brief reports provide timely “instant analysis” of key economic indicators and events, with a one-to-two sentence “DE Assessment” or “DE View.” Updates interpret the data, give insight into immediate market significance, but also provide a perspective on potential longer-term effects. Released intraday.

Search Related:Analytics·Fundamental Research·Macroeconomic Data·Reports

$300 / month

Combination package including Eurozone, US, and UK Economic Indicators products. Brief reports provide timely “instant analysis” of key economic indicators and events, with a one-to-two sentence “DE Assessment” or “DE View.” Updates interpret the data, give insight into immediate market significance, but also provide a perspective on potential longer-term effects. Released intraday.

Search Related:Analytics·Fundamental Research·Macroeconomic Data·Reports

$800 / quarter

Combination package including Eurozone, US, and UK Economic Indicators products. Brief reports provide timely “instant analysis” of key economic indicators and events, with a one-to-two sentence “DE Assessment” or “DE View.” Updates interpret the data, give insight into immediate market significance, but also provide a perspective on potential longer-term effects. Released intraday.

Search Related:Analytics·Fundamental Research·Macroeconomic Data·Reports

$2,500 / yr

Post-event analysis of European Central Bank (ECB), Bank of England (BOE), and other key central bank monetary policy actions.

Search Related:Fixed Income·Fundamental Research·Macroeconomic Data

$2,000/yr

Equity research reports for the consumer, financial, healthcare, industrial, and TMT sectors.

Search Related:Equities·Fundamental Research·Reports

$250 - $2,500 / report

NDR's flagship Advisory publication providing objective asset allocation decisions as well as weekly Advisory summaries of the global and U.S. economy and asset allocation including equities, fixed income, sector allocation, ETFs, and commodities. ETF implementation ideas are also provided.

Search Related:Equities·ETFs·Fixed Income·Fundamental Research·Indices·Macroeconomic Data·Market Data

$300 / month

NDR's flagship Advisory publication providing objective asset allocation decisions as well as weekly Advisory summaries of the global and U.S. economy and asset allocation including equities, fixed income, sector allocation, ETFs, and commodities. ETF implementation ideas are also provided.

Search Related:Equities·ETFs·Fixed Income·Fundamental Research·Indices·Macroeconomic Data·Market Data

$3,300 / year (one month free)

Access our investment research and ratings on 450+ U.S. equity ETFs. Here’s why:

QUESTION: Why shouldn’t ETF research be as good as stock research? Why should ETF investors rely on backward-looking price trends?

ANSWER: They should not.

Don’t judge an ETF by its cover. Take a look inside at its holdings and understand the quality of earnings and valuation of the stocks it holds. We enable you to choose the best ETF based on its stock-picking merits so you do not have to rely solely on backward-looking technical metrics. Cutting-edge technology enables us to scale our forensics accounting expertise so that we can cover enough stocks to cover the ETFs that hold them as well.

 

Search Related:ETFs·Fundamental Research

$20 / month, 14-day free trial

Access our investment research and ratings on 7,000+ U.S. equity mutual funds. Here’s why:

QUESTION: Why shouldn’t mutual fund research be as good as stock research? Why should fund investors rely on backward-looking price trends?

ANSWER: They should not.

Don’t judge a mutual fund by its cover. Take a look inside at its holdings and understand the quality of earnings and valuation of the stocks it holds. We enable you to choose the best fund based on its stock-picking merits so you do not have to rely solely on backward-looking technical metrics. Cutting-edge technology enables us to scale our forensics accounting expertise so that we can cover enough stocks to cover the mutual funds that hold them as well.

 

Search Related:Fundamental Research·Mutual Funds

$20 / month, 14-day free trial

Access our investment research and ratings on 3,000+ U.S. equities. Here’s why:

We find it. You benefit. 

Cutting-edge technology enables us to scale our forensics accounting expertise across 3000+ stocks. We shine a light in the dark corners of SEC filings so our clients can make safer, more informed decisions. 

We do the diligence on earnings quality and valuation to improve your efficiency and help you fulfill fiduciary duties.

 

Search Related:Equities·Fundamental Research

$5 / report

Zacks Equity Research combines the power of the Zacks Rank with the insight provided by experienced equity analysts to create Zacks Research Reports to help you achieve your financial goals.

Search Related:Equities·Featured Products·Fundamental Research·Reports

$99/year

Alpha Deal Group Buy-Side Intelligence Briefs are alpha idea generation analyst reports which cover uniquely positioned companies in major market sectors where current valuation disparities are present.

Search Related:Analytics·Fundamental Research·Reports

Coming Soon

Actionable, macro-trend opinion pieces.

Search Related:Fundamental Research·Reports

$25 per report

Analysis of trades, crop forecasts, statistics and analysis of economic trend and of coffee markets.

Search Related:Fundamental Research·Market Data·Reports

$165 per month, min. 1 year, 7-day free trial

Analysis of trades, crop forecasts, statistics and analysis of economic trend and of corn markets.

Search Related:Fundamental Research·Market Data·Reports

$165 per month, min. 1 year, 7-day free trial

Analysis of trades, crop forecasts, statistics and analysis of economic trend and of soybean markets.

Search Related:Fundamental Research·Market Data·Reports

$165 per month, min. 1 year, 7-day free trial

Analysis of trades, crop forecasts, statistics and analysis of economic trend and of sugar & ethanol markets.

Search Related:Fundamental Research·Market Data·Reports

$165 per month, min. 1 year, 7-day free trial

Post-event analysis of European Central Bank (ECB), Bank of England (BOE), and other key central bank monetary policy actions.

Search Related:Fixed Income·Fundamental Research·Macroeconomic Data

$200 / report

Delivers a Solid Quarter - Conf. Call at 8:30 am EST

March 4, 2015
Maxim Group

EQUITY RESEARCH FIRST LOOK Jason Kolbert (212) 895-3516 jkolbert@maximgrp.com Biotechnology SCMP - NASDAQ March 4, 2015 Closing Price 03/3/2015 $14.97 Rating: Buy 12-Month Target Price: $19.00 52-Wee

PDF (5 pages)
Maxim Group Equity Research Reports $250

Search Related:Biotechnology·FIRST LOOK·SCMP

Raising Target Price to $24 (From $23) on Stronger-Than-Expected EPS Guidance

March 5, 2015
Maxim Group

EQUITY RESEARCH PRICE TARGET CHANGE Brian Kinstlinger, CFA (212)895-3578 bkinstlinger@maximgrp.com Software & Services PRFT - NASDAQ March 5, 2015 Closing Price 03/4/2015 $19.59 Rating: Buy 12-Month

PDF (6 pages)
Maxim Group Equity Research Reports $250

4Q14 Reported: All Systems Go for RI-002 in 2015

March 10, 2015
Maxim Group

EQUITY RESEARCH COMPANY UPDATE Jason Kolbert (212) 895-3516 jkolbert@maximgrp.com Jason McCarthy, Ph.D. (212) 895-3556 jmccarthy@maximgrp.com Biotechnology ADMA - NASDAQ March 10, 2015 Closing Price

PDF (5 pages)
Maxim Group Equity Research Reports $250

Search Related:ADMA·Biotechnology·COMPANY UPDATE

Solid Quarter

March 12, 2015
Maxim Group

EQUITY RESEARCH COMPANY UPDATE John Tinker (212) 895-3735 jtinker@maximgrp.com Media HMTV - NASDAQ March 12, 2015 Closing Price 03/11/2015 $12.34 Rating: Buy 12-Month Target Price: $18.00 52-Week Ran

PDF (6 pages)
Maxim Group Equity Research Reports $250

4th Quarter is Done, and 2015 is Ahead

March 13, 2015
Maxim Group

EQUITY RESEARCH COMPANY UPDATE Jason Kolbert (212) 895-3516 jkolbert@maximgrp.com Jason McCarthy, Ph.D. (212) 895-3556 jmccarthy@maximgrp.com Biotechnology CYTX - NASDAQ March 13, 2015 Closing Price

PDF (10 pages)
Maxim Group Equity Research Reports $250

Search Related:Biotechnology·COMPANY UPDATE·CYTX

IBM Protest on Army Contract is Successful and is an Incremental Negative; CACI Still in the Hunt

March 16, 2015
Maxim Group

EQUITY RESEARCH FIRST LOOK Brian Kinstlinger, CFA (212)895-3578 bkinstlinger@maximgrp.com Software & Services CACI - NYSE March 16, 2015 Closing Price 03/13/2015 $85.97 Rating: Buy 12-Month Target Pr

PDF (5 pages)
Maxim Group Equity Research Reports $250

Initiating Coverage of RiceBran Technologies with a Buy Rating and a $7 Price Target

April 8, 2015
Maxim Group

EQUITY RESEARCH INITIATION Anthony Vendetti (212) 895-3802 avendetti@maximgrp.com Health & Wellness RIBT - NASDAQ April 8, 2015 Closing Price 04/8/2015 $4.01 Rating: Buy 12-Month Target Price: $7.00

PDF (21 pages)
Maxim Group Equity Research Reports $2500

Search Related:Health Care·INITIATION·RIBT

Brainstorm Reports 4Q14: Continuing Phase II Enrollment, Data in 2016

March 26, 2015
Maxim Group

EQUITY RESEARCH COMPANY UPDATE Jason Kolbert (212) 895-3516 jkolbert@maximgrp.com Jason McCarthy, Ph.D. (212) 895-3556 jmccarthy@maximgrp.com Biotechnology BCLI - NASDAQ March 26, 2015 Closing Price

PDF (18 pages)
Maxim Group Equity Research Reports $250

Search Related:BCLI·Biotechnology·COMPANY UPDATE

Assuming Coverage of NovaBay with a Buy Rating and $2 Target Price: The Eyes Have It!

April 29, 2015
Maxim Group

EQUITY RESEARCH ASSUMPTION OF COVERAGE Jason Kolbert (212) 895-3516 jkolbert@maximgrp.com Robert LeBoyer (212)895-3784 rleboyer@maximgrp.com Biotechnology NBY - NYSE April 29, 2015 Closing Price 04/2

PDF (21 pages)
Maxim Group Equity Research Reports $500

The NASH Space Remains Active - Positive for Galmed

March 27, 2015
Maxim Group

EQUITY RESEARCH COMPANY UPDATE Jason Kolbert (212) 895-3516 jkolbert@maximgrp.com Biotechnology GLMD - NASDAQ March 27, 2015 Closing Price 03/26/2015 $10.31 Rating: Buy 12-Month Target Price: $24.00

PDF (10 pages)
Maxim Group Equity Research Reports $250

Search Related:Biotechnology·COMPANY UPDATE·GLMD

Sovaldi Approved in Japan

March 30, 2015
Maxim Group

EQUITY RESEARCH COMPANY UPDATE Jason Kolbert (212) 895-3516 jkolbert@maximgrp.com Biotechnology GILD - NASDAQ March 30, 2015 Closing Price 03/27/2015 $101.00 Rating: Buy 12-Month Target Price: $127.0

PDF (4 pages)
Maxim Group Equity Research Reports $250

Search Related:Biotechnology·COMPANY UPDATE·GILD

Xtandi Outperforms; Raising Price Target Again to $163, from $126

March 30, 2015
Maxim Group

EQUITY RESEARCH PRICE TARGET CHANGE Jason Kolbert (212) 895-3516 jkolbert@maximgrp.com Biotechnology MDVN - NASDAQ March 30, 2015 Closing Price 03/27/2015 $132.00 Rating: Buy 12-Month Target Price: (

PDF (9 pages)
Maxim Group Equity Research Reports $250

Pushing Ahead on All Fronts

March 30, 2015
Maxim Group

EQUITY RESEARCH COMPANY UPDATE Jason Kolbert (212) 895-3516 jkolbert@maximgrp.com Biotechnology IPCI - NASDAQ March 30, 2015 Intraday Price 03/30/2015 $2.73 Rating: Buy 12-Month Target Price: $7.00 5

PDF (13 pages)
Maxim Group Equity Research Reports $250

Search Related:Biotechnology·COMPANY UPDATE·IPCI

3Q14 In Line With our Expectations; Seeking Consistency and Operational Improvement; Maintain Hold

November 6, 2014
Maxim Group

EQUITY RESEARCH COMPANY UPDATE William Bremer (212) 895-3835 wbremer@maximgrp.com Joseph Nelson (212) 895-3657 jnelson@maximgrp.com Industrials & Infrastructure POWR - NYSE November 6, 2014 Closing P

PDF (6 pages)
Maxim Group Equity Research Reports $250

Search Related:COMPANY UPDATE·Industrials·POWR

FY2Q14 First Look: EPS beats but Outlook Tempered. Maintain Buy and $80 PT.

November 6, 2014
Maxim Group

EQUITY RESEARCH FIRST LOOK William Bremer (212) 895-3835 wbremer@maximgrp.com Joseph Nelson (212) 895-3657 jnelson@maximgrp.com Industrials & Infrastructure ENS - NYSE November 6, 2014 Closing Price

PDF (5 pages)
Maxim Group Equity Research Reports $250

Search Related:ENS·FIRST LOOK·Industrials

3Q14 First Look. Reiterate Buy and $5.50 PT.

November 6, 2014
Maxim Group

EQUITY RESEARCH FIRST LOOK Ronald J Barone (214) 794-3267 rbarone@maximgrp.com Joseph Nelson (212) 895-3657 jnelson@maximgrp.com Dry Bulk BALT - NYSE November 6, 2014 Closing Price 11/5/2014 $3.57 Ra

PDF (4 pages)
Maxim Group Equity Research Reports $250

Search Related:BALT·FIRST LOOK·Transportation

3Q14 in Line, Outlook for 4Q14 Improving. Maintain Buy Rating.

November 7, 2014
Maxim Group

EQUITY RESEARCH COMPANY UPDATE Ronald J Barone (214) 794-3267 rbarone@maximgrp.com Joseph Nelson (212) 895-3657 jnelson@maximgrp.com Dry Bulk PRGN - NASDAQ November 7, 2014 Closing Price 11/6/2014 $3

PDF (7 pages)
Maxim Group Equity Research Reports $250

Reports Solid Earnings: Marcellus Basis Weakness Expected to Weigh on F2015 Results

November 7, 2014
Maxim Group

EQUITY RESEARCH COMPANY UPDATE Ronald J Barone (214) 794-3267 rbarone@maximgrp.com Robert Sullivan (917) 655-6989 rsullivan@maximgrp.com Energy NFG - NYSE November 7, 2014 Closing Price 11/6/2014 $70

PDF (8 pages)
Maxim Group Equity Research Reports $250

Search Related:COMPANY UPDATE·Energy·NFG

Reducing Comp and EPS Estimates

November 10, 2014
Maxim Group

EQUITY RESEARCH ESTIMATE CHANGE Rick Snyder (212) 895-3674 rsnyder@maximgrp.com Retail M - NYSE November 10, 2014 Closing Price 11/7/2014 $59.88 Rating: Hold 12-Month Target Price: $48.50 52-Week Ran

PDF (5 pages)
Maxim Group Equity Research Reports $250

VGX-3100 Phase III Registration Coming; Plug and Play Vaccine Platform is Expanding

November 10, 2014
Maxim Group

EQUITY RESEARCH COMPANY UPDATE Jason Kolbert (212) 895-3516 jkolbert@maximgrp.com Biotechnology INO - NYSE November 10, 2014 Closing Price 11/7/2014 $11.23 Rating: Buy 12-Month Target Price: $18.00 5

PDF (5 pages)
Maxim Group Equity Research Reports $250

Search Related:Biotechnology·COMPANY UPDATE·INO

Solid Top-Line Performance, Offset by Aggressive Expansion; Maintain Buy and $6 PT

November 12, 2014
Maxim Group

EQUITY RESEARCH COMPANY UPDATE William Bremer (212) 895-3835 wbremer@maximgrp.com Joseph Nelson (212) 895-3657 jnelson@maximgrp.com Industrials & Infrastructure PFIE - NASDAQ November 12, 2014 Closin

PDF (6 pages)
Maxim Group Equity Research Reports $250

Search Related:COMPANY UPDATE·Industrials·PFIE

Quarter Update: Aramchol Set for Phase IIb

November 13, 2014
Maxim Group

EQUITY RESEARCH COMPANY UPDATE Jason Kolbert (212) 895-3516 jkolbert@maximgrp.com Biotechnology GLMD - NASDAQ November 13, 2014 Closing Price 11/12/2014 $6.03 Rating: Buy 12-Month Target Price: $24.0

PDF (11 pages)
Maxim Group Equity Research Reports $250

Search Related:Biotechnology·COMPANY UPDATE·GLMD

3Q14 Summary; Maintain Buy and $18 Price Target

November 12, 2014
Maxim Group

EQUITY RESEARCH COMPANY UPDATE John Tinker (212) 895-3735 jtinker@maximgrp.com Kevin Rippey (212) 895-3619 krippey@maximgrp.com Media HMTV - NASDAQ November 12, 2014 Closing Price 11/11/2014 $12.70 R

PDF (6 pages)
Maxim Group Equity Research Reports $250

Fiscal 4Q14 Summary; Maintain Buy and $88 Price Target

November 14, 2014
Maxim Group

EQUITY RESEARCH COMPANY UPDATE John Tinker (212) 895-3735 jtinker@maximgrp.com Kevin Rippey (212) 895-3619 krippey@maximgrp.com Media VIAB - NASDAQ November 14, 2014 Closing Price 11/13/2014 $71.20 R

PDF (8 pages)
Maxim Group Equity Research Reports $250

Solid Operational Quarter: Maintain $1.20 Price Target and Buy Rating

November 14, 2014
Maxim Group

EQUITY RESEARCH COMPANY UPDATE Ronald J Barone (214) 794-3267 rbarone@maximgrp.com Robert Sullivan (917) 655-6989 rsullivan@maximgrp.com Energy HTM - NYSE November 14, 2014 Closing Price 11/13/2014 $

PDF (8 pages)
Maxim Group Equity Research Reports $250

Search Related:COMPANY UPDATE·Energy·HTM

Waiting for the Green Light to Start Trials

November 17, 2014
Maxim Group

EQUITY RESEARCH COMPANY UPDATE Jason Kolbert (212) 895-3516 jkolbert@maximgrp.com Biotechnology CFRX - NASDAQ November 17, 2014 Closing Price 11/14/2014 $3.00 Rating: Buy 12-Month Target Price: $16.0

PDF (5 pages)
Maxim Group Equity Research Reports $250

Search Related:Biotechnology·CFRX·COMPANY UPDATE

Roche Ends Prostate Cancer but HBV Continues

November 17, 2014
Maxim Group

EQUITY RESEARCH COMPANY UPDATE Jason Kolbert (212) 895-3516 jkolbert@maximgrp.com Biotechnology INO - NYSE November 17, 2014 Intraday Price 11/17/2014 $10.06 Rating: Buy 12-Month Target Price: $18.00

PDF (5 pages)
Maxim Group Equity Research Reports $250

Search Related:Biotechnology·COMPANY UPDATE·INO

Reports 1Q15 and Sales Force Expansion

November 17, 2014
Maxim Group

EQUITY RESEARCH COMPANY UPDATE Jason Kolbert (212) 895-3516 jkolbert@maximgrp.com Biotechnology ISR - NYSE November 17, 2014 Closing Price 11/14/2014 $1.62 Rating: Buy 12-Month Target Price: $5.00 52

PDF (5 pages)
Maxim Group Equity Research Reports $250

Search Related:Biotechnology·COMPANY UPDATE·ISR

Incremental Bolt on: PFIE Acquires a Little Brother in VIM. Maintain Buy and $6 PT.

November 18, 2014
Maxim Group

EQUITY RESEARCH FIRST LOOK William Bremer (212) 895-3835 wbremer@maximgrp.com Joseph Nelson (212) 895-3657 jnelson@maximgrp.com Industrials & Infrastructure PFIE - NASDAQ November 18, 2014 Closing Pr

PDF (4 pages)
Maxim Group Equity Research Reports $250

Search Related:FIRST LOOK·Industrials·PFIE

If Royalty Rights Sold for $3.3B, How Much Is the CF Franchise Really Worth? A Lot!

December 1, 2014
Maxim Group

EQUITY RESEARCH PRICE TARGET CHANGE Jason Kolbert (212) 895-3516 jkolbert@maximgrp.com Biotechnology VRTX - NASDAQ December 1, 2014 Closing Price 11/28/2014 $117.88 Rating: Buy 12-Month Target Price:

PDF (13 pages)
Maxim Group Equity Research Reports $250
 
Show results for
Refine by
Product Type
Applications
Reports & Files
Publication Date
Last 7 days
Last 30 days
Last 90 days
Last 365 days
Custom
From
To
Vendor
  • Alpha Deal Group
  • Asbury Research
  • BlackOre Research
  • Decision Economics
  • E.B. Capital Markets, LLC
  • Edison Investment Research
  • Infinancials
  • Maxim Group
  • Ned Davis Research Group
  • New Constructs
  • Plunkett Research
  • PureGroup
  • SAFRAS & Mercado
  • Tigress Financial Partners
  • ValuEngine
  • XTF
  • Zacks Investment Research